Clinical Trial Update: Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cannabidiol for cognitive dysfunction in schizophrenia has completed. Results were posted in 2017-06-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Yale University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2017-06-08